We recently published a list of 10 Best Healthcare Stocks For Long-Term Investment. In this article, we are going to take a ...

Coming in No. 3 on Fast Company's Queer 50 list, is Martine Rothblatt, the founder and CEO of United Therapeutics. She's also a lawyer, satellite entrepreneur, and futurist. See the innovative ...

Shares of United Therapeutics fell on pace for the largest percent decrease in three years after the company's fourth-quarter earnings fell short of expectations. The stock was down 10% ...

Shares of biotechnology company United Therapeutics (NASDAQ:UTHR) fell 10.9% in the afternoon session after the company reported disappointing fourth-quarter results: EPS missed analysts ...

UNITED THERAPEUTICS ($UTHR) posted quarterly earnings results on Wednesday, February 26th. The company reported earnings of $6.19 per share, missing estimates of $6. ...

Equities research analysts at Zacks Research lowered their Q1 2025 earnings per share estimates for shares of United ...

United Therapeutics is highly undervalued with a P/E of 16x and EV/EBITDA of 8.64x, compared to sector medians of 28x and 15.15x, respectively. The company shows strong revenue growth, driven by ...

United Therapeutics’ UTHR fourth-quarter 2024 earnings of $6.19 per share beat the Zacks Consensus Estimate of $6.10. Earnings rose 42% year over year on the back of higher product sales.

In trading on Wednesday, shares of United Therapeutics Corp (Symbol: UTHR) entered into oversold territory, hitting an RSI reading of 28.5, after changing hands as low as $319.02 per share.